Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/XU3Oi8zAbMc/237807.php
Thursday, 17 November 2011
$3m Raised For Alzheimer's Drug
The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson's drug that has proven to have a disease-modifying effect. Novartis's Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer's disease...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment